Equities Analysts Offer Predictions for JNJ Q1 Earnings

Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Zacks Research decreased their Q1 2025 EPS estimates for Johnson & Johnson in a research report issued on Wednesday, February 12th. Zacks Research analyst K. Shah now expects that the company will earn $2.60 per share for the quarter, down from their prior estimate of $2.63. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q3 2025 earnings at $2.78 EPS, Q4 2025 earnings at $2.48 EPS, FY2025 earnings at $10.55 EPS, Q1 2026 earnings at $2.66 EPS, Q2 2026 earnings at $2.76 EPS, Q3 2026 earnings at $2.79 EPS, Q4 2026 earnings at $2.83 EPS and FY2027 earnings at $11.48 EPS.

Several other equities research analysts have also recently commented on JNJ. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Guggenheim increased their price target on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $157.24 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a market cap of $378.58 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 2.46 and a beta of 0.52. The stock has a 50-day moving average price of $147.58 and a 200 day moving average price of $156.00.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 EPS.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. AMF Tjanstepension AB grew its stake in shares of Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after buying an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth about $209,000. Wealth Group Ltd. bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $213,000. Wedge Capital Management L L P NC lifted its stake in Johnson & Johnson by 2.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock valued at $655,000 after purchasing an additional 86 shares during the last quarter. Finally, Creative Planning grew its holdings in Johnson & Johnson by 4.3% during the third quarter. Creative Planning now owns 988,403 shares of the company’s stock worth $160,181,000 after purchasing an additional 41,082 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.15%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.